Bill Summary
The resolution urges the Director of the Food and Drug Administration (FDA) to reassess the safety of all chemical abortion drugs, particularly in light of new independent studies that raise concerns about their safety and efficacy. The resolution highlights changes made during the Obama and Biden administrations that expanded access to these drugs by eliminating certain requirements for in-person administration and reporting adverse effects. It expresses apprehensions about potential violations of federal law, risks of coercion and misuse, and the ethical implications of taxpayer funding for providers of these drugs. It notes that chemical abortions now constitute over half of all abortions in the U.S. and points out a recent approval of a generic version of mifepristone, which may lead to an increase in abortions and associated risks for women. The resolution calls for the FDA to conduct a thorough safety review and make the findings publicly available.
Possible Impacts
The resolution you provided raises several concerns and proposals regarding the safety and regulation of chemical abortion drugs. Here are three examples of how this legislation could affect people:
1. **Impact on Women's Health and Safety**: If the FDA reevaluates the safety of chemical abortion drugs and finds that they pose a higher risk of complications than previously reported, this could lead to stricter regulations or restrictions on their use. Women seeking these medications might face increased barriers to access or be required to undergo more medical supervision, thereby potentially affecting their ability to make timely decisions about their reproductive health.
2. **Changes in Availability and Access**: The resolution calls for a reexamination of the expanded access to chemical abortion drugs, including mail distribution and reduced in-person requirements. If the FDA decides to reverse these policies, it could significantly limit access, especially in rural or underserved areas where healthcare providers are scarce. This could disproportionately affect low-income individuals and those without easy access to healthcare facilities.
3. **Psychological and Emotional Impact**: The resolution highlights concerns about the emotional harm that women and girls might experience due to potential complications from chemical abortions. If the safety review identifies significant risks, it could lead to increased public fear or stigma surrounding the use of these drugs. This might affect women's mental health, especially if they feel pressured or coerced into making decisions about their pregnancies without adequate support or information. Additionally, women may feel less confident in seeking these services if they believe the risks are higher than previously understood.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 803 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. RES. 803
Urging the Director of the Food and Drug Administration to reevaluate
the safety of all chemical abortion drugs in light of recent
independent studies, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
October 10, 2025
Mr. Rose (for himself, Mrs. Harshbarger, Mr. Carter of Georgia, Mr.
LaMalfa, Mrs. Biggs of South Carolina, Mr. Moore of Alabama, Ms.
Hageman, and Mr. Grothman) submitted the following resolution; which
was referred to the Committee on Energy and Commerce
_______________________________________________________________________
RESOLUTION
Urging the Director of the Food and Drug Administration to reevaluate
the safety of all chemical abortion drugs in light of recent
independent studies, and for other purposes.
Whereas the Obama administration expanded access to chemical abortion drugs by
removing in-person administration requirements, eliminating requirements
for prescribers to report serious adverse effects, and removing follow-
up care obligations;
Whereas the Biden administration further expanded access to chemical abortion
drugs by removing in-person dispensing requirements, permitting these
drugs to be distributed by mail;
Whereas the expansion of access to chemical abortion drugs has raised serious
concerns regarding potential violations of Federal law, increased risks
of coercion and domestic abuse, and even intentional misuse resulting in
harm or death;
Whereas chemical abortions now account for more than half of all abortions
performed in the United States;
Whereas many providers prescribing chemical abortion drugs receive taxpayer
funding, raising ethical and legal concerns regarding the use of public
funds;
Whereas, on September 30, 2025, the Food and Drug Administration approved a new
generic version of mifepristone, further expanding the availability of
chemical abortion drugs;
Whereas this approval will likely contribute to a significant increase in the
number of unborn children lost to abortion, and poses a risk of
potential physical and emotional harm to women and girls, while
undermining pro-life laws enacted by numerous States; and
Whereas independent research suggests that chemical abortions carry a rate of
serious complications that is 22 times higher than what is currently
reported by the Food and Drug Administration and drug manufacturers:
Now, therefore, be it
Resolved, That the House of Representatives urges the Director of
the Food and Drug Administration--
(1) to reevaluate the safety of all chemical abortion drugs
in light of recent independent studies; and
(2) to publicly release a full safety review of such drugs
that includes real-world outcomes and complications.
<all>